Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10652839 | 0.98 | CHRM3 (0.57) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL7412192 | 0.89 | CHRM3 (0.63) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| Bromide SCHEMBL10460358 | 0.87 | CHRM3 (0.61) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL7412843 | 0.86 | HTR2C (0.59) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| Gaboxadol SCHEMBL5533785 | 0.84 | CHRM3 (0.46) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| Gaboxadol SCHEMBL247815 | 0.84 | CHRM3 (0.46) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| Gaboxadol SCHEMBL23851948 | 0.82 | CHRM3 (0.45) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| Gaboxadol SCHEMBL1403323 | 0.82 | CHRM3 (0.45) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| Gaboxadol SCHEMBL3980688 | 0.82 | CHRM3 (0.45) | CHRM3CHRM5CHRM1CHRM2CHRM4 | |
| Gaboxadol SCHEMBL3983776 | 0.82 | CHRM3 (0.45) | CHRM3CHRM5CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1839657-A2 | A method for treating vascular headaches | THE GENERAL HOSPITAL CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| EP-3596060-B1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-09-20 | — | — | EP | disclosed |
| EP-3353176-B1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-10800786-B2 | Bicyclic compounds as ATX inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200087307-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20160120995-A1 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | MEDWELL LAB LTD (IL) | 2016-05-05 | — | — | US | disclosed |
| US-9108937-B2 | Positive allosteric modulators of mGluR2 | MERCK SHARP & DOHME CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108937-B2 | Positive allosteric modulators of mGluR2 | MERCK SHARP & DOHME CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108937-B2 | Positive allosteric modulators of mGluR2 | MERCK SHARP & DOHME CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2542083-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-0631623-A4 | DNA ENCODING TAURINE AND GABA TRANSPORTERS AND USES THEREOF. | SYNAPTIC PHARMA CORP (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996015782-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0631623-A1 | DNA ENCODING TAURINE AND GABA TRANSPORTERS AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-01-04 | — | — | EP | disclosed |
| WO-1993018143-A1 | DNA ENCODING TAURINE AND GABA TRANSPORTERS AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1993-09-16 | — | — | WO | disclosed |
| US-4761429-A | ALCOHOL CRAVING | BIESER, ALBERT H. | 1988-08-02 | — | — | US | disclosed |
| EP-0126654-B1 | TETRAHYDROISOXAZOLO(4,5-C)PYRIDINE DERIVATIVES AND PREPARATION THEREOF | H. LUNDBECK A/S (DK) | 1988-05-04 | — | — | EP | disclosed |
| EP-0000338-B1 | ISOXAZOLO(5,4-C)PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | H.Lundbeck & Co., A/S (DK) | 1981-11-25 | — | — | EP | disclosed |
| US-4301287-A | FOR TREATMENT OF PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | H. LUNDBECK & CO. A/S (DK) | 1981-11-17 | — | — | US | disclosed |
| US-4278676-A | NERVOUS SYSTEM DISORDERS, CYCLIZATION, HYDROLYSIS | H. LUNDBECK & CO. A/S (DK) | 1981-07-14 | — | — | US | disclosed |
| EP-0000338-A2 | Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them | H.Lundbeck & Co., A/S (DK) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800786-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN2L, ATXN10 | CHRM3 952/4885CHRM5 550/4885CHRM1 807/4885 |
| US-20160120995-A1 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | ALOX5, ALOX15B, ALOX15 | CHRM3 489/4885CHRM5 203/4885CHRM1 430/4885 |
| US-20200087307-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN2L, ATXN10 | CHRM3 952/4885CHRM5 550/4885CHRM1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.